Wellington Management Group LLP Reports 7.8% Stake in Crinetics Pharmaceuticals, Inc.

Wellington Management Group LLP, along with its affiliated holding companies and investment advisers, filed a Schedule 13G/A on May 15, 2026, disclosing an increased position in Crinetics Pharmaceuticals, Inc. (CRNX). As of the event date of March 31, 2026, Wellington reported beneficial ownership of 8,157,204 shares of common stock, representing a 7.8% ownership stake in the company. This represents a significant increase from the previous reported position of zero shares. The filing was made jointly by Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP. The reporting entities indicated that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. Wellington Management Company LLP specifically reported shared voting power over 7,085,570 shares and shared dispositive power over 7,695,986 shares, while the parent holding companies reported shared power over the full 8,157,204 share amount.